XENE NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Xenon Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 65.42 USD
-4.2% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 25.0% above the Trend Line and sits at 83.0% of its 52-week range. The latest completed week returned -4.2%, after a 9.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 65 out of 100
Latest Close 65.42 USD 24 Jul 2026
1W Return -4.2% latest completed week
4W Return 9.5% short-term follow-through
12W Return 16.6% quarterly tape
Trend Breadth 86.5% 45 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 45-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 15 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.2% Latest completed week; four-week move 9.5%. Indicator stack 93/74 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 53/100 conviction; expected move 13.3%. News sentiment 55/100 57 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 25.0% above the Trend Line and sits at 83.0% of its 52-week range. The latest completed week returned -4.2%, after a 9.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6612-week average 0.67

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.66Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1515 reversal markers

No recent accumulation markers. 15 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 9.5% over four weeks, 16.6% over 12 weeks, and 115.9% over one year. The current trend has remained active for 45 consecutive weeks.

Performance by holding period

1W-4.2%
4W9.5%
12W16.6%
26W56.7%
52W115.9%
Active trend streak45 weeks
Active weeks in one year45
Trend breadth86.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.42Latest activity-pressure read.
Pressure change211.3%Four-week change in activity pressure.
Leadership28.43Latest relative-leadership reading.
RS change57.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength28/100Blend of value, momentum, and quality. Underlying universe rank 73; rank 1 is best.
Value40/100Relative valuation strength. Underlying universe rank 61; rank 1 is best.
Quality39/100Profitability and accounting quality. Underlying universe rank 62; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-37.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.8%
Net share repurchases relative to market value.
Shareholder yield
-1.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

XENE shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.05, expected move of 13.3%, and Sharemaestro trend signal active.

Conviction53/100
Expected move13.3%
Put/call volume0.05
Pressure100
Speculation8
Volatility84
Trend agreement3
Open options detail
Insider activity18 / 2

18 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 57 relevant articles.

17 positive · 38 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move13.3%Nearest-chain priced movement where available.
52-week drawdown-10.0%Distance below the 52-week high.
13-week volatility5.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+31.7%Week of 13 Mar.
Worst week-7.5%Week of 24 Apr.
Latest week-4.2%Week of 24 Jul.

Shape of recent returns

Strong gains4
Modest gains12
Flat weeks0
Modest losses7
Sharp losses3
Recent vol5.4%13-week weekly-return volatility.
Base vol6.3%52-week weekly-return volatility.
Up/down split34/18Count of positive and negative weeks in the 52-week window.
Average skew4.3% / -3.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape66/100

Trend, activity pressure, participation, and risk combine to a 66/100 tape read.

 Indicator analysis70/100

Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 12/12.

Activity pressure 0.66; 15 reversal markers Factors35/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 78; Small Cap Core rank 60 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options37/100

XENE shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.05, expected move of 13.3%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 13.3% Sentiment55/100

Weighted news tone is neutral across 57 relevant articles.

Xenon Pharmaceuticals Inc (XENE) Institutional Confidence Insiders18 / 2

18 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202665.42 USD-4.2%52.35 USD41.47 USD0.4228.433.1MOn
17 Jul 202668.26 USD-1.0%51.66 USD41.28 USD0.4433.316.2MOn
10 Jul 202668.92 USD13.1%50.85 USD41.08 USD0.0730.4212.1MOn
3 Jul 202660.96 USD2.0%50.03 USD40.89 USD-0.2918.595.7MOn
26 Jun 202659.74 USD12.9%49.49 USD40.75 USD-0.3818.0214.7MOn
19 Jun 202652.91 USD1.6%48.99 USD40.61 USD-0.400.515.0MOn
12 Jun 202652.10 USD0.7%48.60 USD40.53 USD-0.131.906.3MOn
5 Jun 202651.73 USD-5.5%48.22 USD40.46 USD0.103.798.0MOn
29 May 202654.73 USD1.0%47.77 USD40.39 USD0.375.257.9MOn
22 May 202654.17 USD-0.4%47.35 USD40.29 USD0.537.724.7MOn
15 May 202654.39 USD-3.6%46.90 USD40.20 USD0.699.984.6MOn
8 May 202656.44 USD0.6%46.48 USD40.12 USD0.9214.344.3MOn
1 May 202656.13 USD1.6%45.92 USD40.01 USD1.0520.216.3MOn
24 Apr 202655.24 USD-7.5%45.37 USD39.92 USD1.1420.293.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.